bispecific – Talk Bio

Royalty Pharma Buys $885M Imdelltra Royalty Stake from BeOne

2 weeks ago talkbio0Tagged amgen, bispecific, DLL3, DLL3 gene, ES-SCLC, Imdelltra, Malignant neoplasm of lung, Royalty, Small cell carcinoma of lung, upfront

BeOne Medicines; Imdelltra; Amgen; Royalty Pharma; $885 million upfront; lung cancer; royalty deal; DLL3 bispecific; small cell lung cancer; ES-SCLC

Cullinan Inks $700M Deal for BCMA Bispecific to Expand Autoimmune T-Cell Engager Portfolio

3 months ago talkbio0Tagged Autoimmune Diseases, biotech partnerships, bis(3-bis(4-chlorophenyl)methyl-4-dimethylaminophenyl)amine, bispecific, CD19xCD3, Clinical Development, CLN-978, Cullinan, Genrix Bio, Multiple Myeloma, T-Cell engager, velinotamig

Cullinan Therapeutics; Genrix Bio; BCMA bispecific; velinotamig; T-cell engager; autoimmune disease; CD19xCD3; CLN-978; multiple myeloma; clinical development; biotech partnerships

BioNTech Invests $800M in PD-L1xVEGF-A Bispecific, Aiming to Challenge Keytruda Dominance

10 months ago talkbio0Tagged BioNTech, Biotheus, bispecific, Drug Industry, Immunotherapy for cancer, Keytruda, PD-L1xVEGF-A

BioNTech, Keytruda, PD-L1xVEGF-A bispecific, Biotheus, cancer immunotherapy, pharmaceutical industry